Before the opening bell, International Stem Cell Corp. (OTCQB: ISCO) announced that the first patient in its ongoing phase I clinical trial of human parthenogenetic neural stem cells (ISC-hpNSC) for the treatment of moderate to severe Parkinson’s disease has undergone a successful intracranial transplant of ISC-hpNSC at the Royal Melbourne Hospital in Australia. This milestone […]
The Stocks To Buy Now Blog
Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.